AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 51 min read$VSTM

Paterson Dan sold $8K of VSTM

Paterson Dan (President and CEO) sold 1,302 shares of Verastem, Inc. (VSTM) at $5.81 on 2026-08-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Paterson Dan
Published Aug 5, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 6:26 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$VSTM
Neutral
high confidence
Mentioned
$VSTM
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$VSTMNeutralLow
01

Why it matters

The newest fact is the CEO’s Aug 3 open-market sale amount and price, filed on Aug 5. This can influence short-term sentiment but does not introduce new business or financial guidance.

02

Market read

Traders may note insider selling, but the 10b5-1 structure reduces interpretive weight versus an unplanned sale.

03

What to watch

The article provides only the sale details, not total insider ownership changes over time or any concurrent company-specific catalysts.

Relevance 2/10Novelty 3/10Timing: Filed Aug 5, covering an Aug 3 sale.

Background

The article is a SEC Form 4 insider transaction disclosure for Verastem, Inc. (VSTM).

Company-level read

Ticker impact

$VSTMNeutralHigh confidence
Context

Verastem CEO Paterson Dan filed a Form 4 open-market sale of 1,302 shares at $5.81 on Aug 3 under a 10b5-1 plan.

Expected impact

Low likelihood of sustained price impact; any reaction is likely brief and sentiment-driven.

Evidence & confidence

The filing is a routine 10b5-1 planned sale by the CEO, with no accompanying guidance, operational change, or transaction terms indicating new corporate risk.

Market effects

Sector

Minimal. Insider 10b5-1 sales are common and do not typically signal sector-wide changes.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is explicitly under a pre-arranged 10b5-1 plan, it may reflect liquidity planning rather than bearish expectations.

Key entities

  • issuer
    Verastem, Inc.

    Company whose CEO insider sale is disclosed on Form 4.

  • insider
    Paterson Dan

    President and CEO who sold 1,302 shares at $5.81 under a 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

VSTM insider trading history →

Related articles

AUG 20
$VSTMHighAI 8/10

Verastem (VSTM) Q2 2026 Earnings Call Transcript

Verastem (VSTM) reported Q2 2026 revenue of $40.1M, including $25.1M from product sales and a $15M milestone. Net loss was $30.6M, down from $41.3M YoY. Cash position is $136.4M, with a pro forma balance of $201.4M. The company expects cash runway into 2H 2027 and LGSOC business self-sustainability by year-end. Clinical trials for VS-7375 are progressing, with Phase III plans for 2027.

aol.com3 min
AUG 14
$VSTMMedAI 8/10

Verastem (VSTM) Q2 2026 Earnings Call Transcript

Verastem (VSTM) reported Q2 2026 net product revenue of $25.1M from the AVMAPKI FAKZYNJA CO-PACK launch and total revenue of $40.1M, including a $15M Secura Bio milestone. Non-GAAP adjusted net loss was $30.6M ($0.31/share). Cash and investments were $136.4M; pro forma cash $201.4M. VS-7375 Phase II trials advanced.

fool.com14 min
AUG 7
$VSTMMedAI 8/10

Verastem Oncology Q2 2026 Earnings: Revenue Beats $40.1 Million

Verastem Oncology (Nasdaq: VSTM) reported Q2 2026 results: GAAP EPS -$0.35 and non-GAAP EPS -$0.31, with revenue of $40.1 million. Revenue rose from $2.1 million a year earlier, driven by AVMAPKI FAKZYNJA CO-PACK net product revenue of $25.1 million and a $15.0 million COPIKTRA milestone. Cash and investments were $136.4 million at June 30, 2026.

sci-tech-today.com6 min
AUG 6
$VSTMMed

Verastem, Inc. (VSTM): Results of Operations and Financial Condition

Verastem, Inc. (VSTM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates AVMAPKI® FAKZYNJA® CO-PACK net product revenue of $25.1 million First patients dosed in all three TARGET-D Phase 2 registration-directed clinical trials evaluating

SEC EDGAR 8-K6 min
JUL 21
$OFIXMed

These 7 Small Caps Are On Fire In July: Here's Why - ExxonMobil Holdings (NYSE:XOM), Vertex Pharmaceutica

The Russell 2000 stayed near 3,000 with little movement, while seven small-cap stocks gained at least 28% in four sessions. The article cites July surges for Orthofix (OFIX) on CMS reimbursement reversal, REGENXBIO (RGNX) on FDA resubmission alignment and AbbVie milestone, Verastem (VSTM) on short-squeeze setup, ADC Therapeutics (ADCT) rebound, Sable Offshore (SOC) refinancing, Rapid7 (RPD) takeover speculation, and Crinetics (CRNX) surge toward an offer price.

benzinga.com7 min
JUN 17
$VSTMMed

Verastem Stock Jumps As Data Shows Strong Survival Trends In Pancreatic Cancer - Verastem (NASDAQ:VSTM)

Verastem (NASDAQ:VSTM) shares rose after updated RAMP 205 pancreatic cancer trial data. The company reported 86% overall survival at six months and 68% progression-free survival at six months; 83% of patients had tumor shrinkage at the recommended phase 2 P2D dose, with no new safety signals. The update also noted 90% metastatic at diagnosis and 9 patients still on treatment.

benzinga.com4 min